Quantcast

Novartis’s certain cancer combination approved by FDA; fourth actionable genomic biomaker in metastatic NSCLC

Novartis was cleared on Thursday by the US Food and Drug Administration (FDA) for combination of Tafinlar (dabrafenib) with Mekinist (trametinib) for treating metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express the BRAF V600E mutation, which is fourth actionable genomic biomaker in metastatic NSCLC

Read more

Shield Therapeutics: Ferric maltol may be effective in patients with active inflammatory markers

Shield Therapeutics’s study suggests that ferric maltol may be effective in patients with active inflammatory markers, and that the ongoing comparative trial of ferric maltol against iv iron will be useful to challenge the prevalent doctrine prohibiting treatment of patients with active systemic inflammation with oral iron.

Read more